We critically examine how developmental signaling pathways, cellular plasticity, and immune-vascular context shape tumor behavior and therapeutic vulnerability, with a focus on emerging targeted, anti-angiogenic, immune, and epigenetic strategies.<h4>Results</h4>Hepatoblastoma is characterized by aberrant activation of key developmental pathways, including Wnt/β-catenin, Hippo-YAP, IGF, and mTOR signaling, which cooperate to sustain proliferation, stem-like phenotypes, and treatment resistance. This evidence concerns the gene MTOR and hepatoblastoma.